Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease.

Front Cardiovasc Med · 2021 · PMC8558356 · PMID 34733897

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significancep = 0.05actually significant

Apixaban reduced the risk of major bleeding by 22%, but the difference did not reach statistical significance (aHR, 0.78; 95% CI, 0.60–1.00; p = 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.